Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Andrew Glasebrook
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Anatomy
Physiology
Procedures
Sign-in to see full Profile
Network (preview)
12
Bryant, Henry
10
Short, LL
8
Yang, NN
7
Sato, Masahiko
7
Phillips, DL
5
Na, Songqing
5
Song, Ho Yeong
5
Grese, Timothy
4
Yang, Derek
4
Palkowitz, Alan
4
Liu, Jinqi
4
Magee, David
4
Cole, Harlan
3
Cullinan, GJ
3
Dodge, Jeffrey
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Andrew Glasebrook (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2005: Schmidt Clint S; Zhao Jingyong; Chain Jana; Hepburn Deena; Gitter Bruce; Sandusky George; Chintalacharuvu Subba; Glasebrook Andrew; Na Songqing
Resistance to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis by death receptor 6-deficient mice.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(4):2286-92.
-
2003: Wortinger Mark A; Foley Joseph W; Larocque Patrick; Witcher Derrick R; Lahn Michael; Jakubowski Joseph A; Glasebrook Andrew; Song Ho Yeong
Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.
Immunology 2003;110(2):225-33.
-
2003: Liu Jinqi; Schmidt Clint S; Zhao Feisha; Okragly Angela J; Glasebrook Andrew; Fox Niles; Galbreath Elizabeth; Zhang Qing; Song Ho Yeong; Na Songqing; Yang Derek D
LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function.
International immunology 2003;15(7):861-70.
-
2003: Schmidt Clint S; Liu Jinqi; Zhang Tonghai; Song Ho Yeong; Sandusky George; Mintze Karen; Benschop Robert J; Glasebrook Andrew; Yang Derek D; Na Songqing
Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6.
The Journal of experimental medicine 2003;197(1):51-62.
-
2002: Suh Nanjoo; Lamph William W; Glasebrook Andrew L; Grese Timothy A; Palkowitz Alan D; Williams Charlotte R; Risingsong Renee; Farris M Rendi; Heyman Richard A; Sporn Michael B
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3270-5.
-
2002: Liu Jinqi; Heuer Josef G; Na Songqing; Galbreath Elizabeth; Zhang Tonghai; Yang Derek D; Glasebrook Andrew; Song Ho Yeong
Accelerated onset and increased severity of acute graft-versus-host disease following adoptive transfer of DR6-deficient T cells.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(7):3993-8.
-
2002: Racke Margaret M; Mosior Marian; Kovacevic Steve; Chang Chan Hsin S; Glasebrook Andrew L; Roehm Neal W; Na Songqing
Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells.
Journal of neurochemistry 2002;80(6):1039-48.
-
2001: Suh N; Glasebrook A L; Palkowitz A D; Bryant H U; Burris L L; Starling J J; Pearce H L; Williams C; Peer C; Wang Y; Sporn M B
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
Cancer research 2001;61(23):8412-5.
-
2001: Grese T A; Adrian M D; Phillips D L; Shetler P K; Short L L; Glasebrook A L; Bryant H U
Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms).
Journal of medicinal chemistry 2001;44(17):2857-60.
-
2001: Liu J; Na S; Glasebrook A; Fox N; Solenberg P J; Zhang Q; Song H Y; Yang D D
Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice.
Immunity 2001;15(1):23-34.
-
1999: Bryant H U; Glasebrook A L; Yang N N; Sato M
An estrogen receptor basis for raloxifene action in bone.
The Journal of steroid biochemistry and molecular biology 1999;69(1-6):37-44.
-
1999: Schmid C R; Glasebrook A L; Misner J W; Stephenson G A
Synthesis and biological activity of trans-2,3-dihydroraloxifene.
Bioorganic & medicinal chemistry letters 1999;9(8):1137-40.
-
1998: Grese T A; Pennington L D; Sluka J P; Adrian M D; Cole H W; Fuson T R; Magee D E; Phillips D L; Rowley E R; Shetler P K; Short L L; Venugopalan M; Yang N N; Sato M; Glasebrook A L; Bryant H U
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Journal of medicinal chemistry 1998;41(8):1272-83.
-
1997: Grese T A; Sluka J P; Bryant H U; Cullinan G J; Glasebrook A L; Jones C D; Matsumoto K; Palkowitz A D; Sato M; Termine J D; Winter M A; Yang N N; Dodge J A
Molecular determinants of tissue selectivity in estrogen receptor modulators.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(25):14105-10.
-
1997: Palkowitz A D; Glasebrook A L; Thrasher K J; Hauser K L; Short L L; Phillips D L; Muehl B S; Sato M; Shetler P K; Cullinan G J; Pell T R; Bryant H U
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Journal of medicinal chemistry 1997;40(10):1407-16.
-
1997: Dodge J A; Lugar C W; Cho S; Short L L; Sato M; Yang N N; Spangle L A; Martin M J; Phillips D L; Glasebrook A L; Osborne J J; Frolik C A; Bryant H U
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
The Journal of steroid biochemistry and molecular biology 1997;61(1-2):97-106.
-
1997: Yang N N; Venugopalan M; Hardikar S; Glasebrook A
Correction: raloxifene response needs more than an element.
Science (New York, N.Y.) 1997;275(5304):1249.
-
1997: Grese T A; Cho S; Finley D R; Godfrey A G; Jones C D; Lugar C W; Martin M J; Matsumoto K; Pennington L D; Winter M A; Adrian M D; Cole H W; Magee D E; Phillips D L; Rowley E R; Short L L; Glasebrook A L; Bryant H U
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Journal of medicinal chemistry 1997;40(2):146-67.
-
1997: Kauffman R F; Bensch W R; Roudebush R E; Cole H W; Bean J S; Phillips D L; Monroe A; Cullinan G J; Glasebrook A L; Bryant H U
Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.
The Journal of pharmacology and experimental therapeutics 1997;280(1):146-53.
-
1996: Zuckerman S H; Ahmari S E; Bryan-Poole N; Evans G F; Short L; Glasebrook A L
Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxemia.
Inflammation 1996;20(6):581-97.
-
1996: Shiau S P; Glasebrook A; Hardikar S D; Yang N N; Hershberger C L
Activation of the human estrogen receptor by estrogenic and antiestrogenic compounds in Saccharomyces cerevisiae: a positive selection system.
Gene 1996;179(2):205-10.
-
1996: Dodge J A; Glasebrook A L; Magee D E; Phillips D L; Sato M; Short L L; Bryant H U
Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat.
The Journal of steroid biochemistry and molecular biology 1996;59(2):155-61.
-
1996: Apelgren L D; Bailey D L; Fouts R L; Short L; Bryan N; Evans G F; Sandusky G E; Zuckerman S H; Glasebrook A; Bumol T F
The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.
Cellular immunology 1996;173(1):55-63.
-
1996: Yang N N; Venugopalan M; Hardikar S; Glasebrook A
Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene.
Science (New York, N.Y.) 1996;273(5279):1222-5.
-
1996: John V; Hock J M; Short L L; Glasebrook A L; Galvin R J
A role for CD8+ T lymphocytes in osteoclast differentiation in vitro.
Endocrinology 1996;137(6):2457-63.
-
1996: Yang N N; Bryant H U; Hardikar S; Sato M; Galvin R J; Glasebrook A L; Termine J D
Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Endocrinology 1996;137(5):2075-84.
-
1995: Zuckerman S H; Bryan-Poole N; Evans G F; Short L; Glasebrook A L
In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists.
Immunology 1995;86(1):18-24.
-
1995: Fuchs-Young R; Glasebrook A L; Short L L; Draper M W; Rippy M K; Cole H W; Magee D E; Termine J D; Bryant H U
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Annals of the New York Academy of Sciences 1995;761():355-60.
Sign-in to see more
